Overview

A Phase I Study of AK159 in Healthy Postmenopausal Women

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.
Phase:
Phase 1
Details
Lead Sponsor:
Asahi Kasei Pharma Corporation
Treatments:
Teriparatide